Kinase-targeted therapy in subsets of colorectal cancer

Barila, Patricia M. Gomez; Medema, Jan Paul

doi:10.18632/oncoscience.580

Cited by 1 publication

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR (epidermal growth factor receptor) is a transmembrane protein that plays a significant role in regulating cell growth and differentiation. 134 EGFR inhibitors, such as cetuximab and panitumumab, target this receptor, aiming to block downstream signaling and inhibit tumor cell proliferation. However, the effectiveness of these therapies is contingent on the mutation status of the RAS pathway, which includes genes, such as KRAS and NRAS.…”

Section: Egfr Inhibitors and Ras Pathwaymentioning

confidence: 99%

“…Colorectal cancer is a genetically heterogeneous disease, and understanding the genetic alterations in the RAS pathway is pivotal for tailoring therapy to individual patients. EGFR (epidermal growth factor receptor) is a transmembrane protein that plays a significant role in regulating cell growth and differentiation . EGFR inhibitors, such as cetuximab and panitumumab, target this receptor, aiming to block downstream signaling and inhibit tumor cell proliferation.…”

Section: Targeted Therapies In Precision Medicinementioning

confidence: 99%

See 1 more Smart Citation

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

show abstract

Section: Egfr Inhibitors and Ras Pathwaymentioning

confidence: 99%

Section: Targeted Therapies In Precision Medicinementioning

confidence: 99%